Singer MA, et al. - Researchers assessed the visual outcomes of the FAME study (0.2 μg/day fluocinolone acetonide [FAc]) vs the Protocol I (0.5 mg ranibizumab plus deferred laser) via the area under the curve (AUC) analysis method. They noted that FAc and ranibizumab plus deferred laser were similar, but FAc allowed for fewer injections in pseudophakic and chronic diabetic macular edema (DME) subgroups. Nonetheless, ranibizumab plus deferred laser and FAc were not found to be significantly different for subgroups of pseudophakic eyes, eyes with chronic DME, and pseudophakic eyes with chronic DME.